Latest Press Releases Mar 27 2023 Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes Read More Mar 16 2023 Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147) Read More Mar 09 2023 Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes Read More Feb 21 2023 Vertex to Present at Cowen’s 43rd Annual Health Care Conference on March 7 Read More Feb 07 2023 Vertex Reports Fourth Quarter and Full Year Financial 2022 Results Read More Jan 17 2023 Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7 Read More Load More Recent Media Library Items View All Date - Any -20212022 Tags Download LibraryImages Our mRNA Investigational Therapy (VX-522) Infographic Download 9 MB Date - Any -20212022 Tags Download LibraryImages Reshma Kewalramani, M.D. Chief Executive Officer and President Download 10 MB Date - Any -20212022 Tags Download LibraryImages Vertex International Headquarters Paddington – Lobby Padding reception entrance Download 915 KB Date - Any -20212022 Tags Download LibraryImages Vertex Logo with Tagline Download 2 MB | 2951 x 1952 Mediainfo@VRTX.com
Mar 27 2023 Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex’s Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes Read More
Mar 16 2023 Vertex Announces Publication in New England Journal of Medicine of Results from Phase 2 Study of Inaxaplin (VX-147) Read More
Mar 09 2023 Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes Read More
Jan 17 2023 Vertex to Announce Fourth Quarter and Full Year 2022 Financial Results on February 7 Read More
